Lirentelimab (ak002)    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
98Eosinophilic gastrointestinal disease2

98. Eosinophilic gastrointestinal disease    [ 128 clinical trials,   147 drugs,   (DrugBank: 40 drugs),   34 drug target genes,   132 drug target pathways]
Searched query = "Eosinophilic gastrointestinal disease", "Eosinophilic gastroenteritis", "Eosinophilic esophagitis", "Eosinophilic colitis", "Eosinophilic gastro-intestinal disorder", "EGID", "Neonatal food-protein induced enterocolitis", "N-FPIES"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 128 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04322708
(ClinicalTrials.gov)
July 6, 202024/3/2020A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic EsophagitisA Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic EsophagitisEosinophilic EsophagitisOther: Placebo;Drug: lirentelimab (AK002)Allakos, Inc.NULLRecruiting12 Years80 YearsAll300Phase 2;Phase 3United States;Australia;Netherlands
2NCT04322604
(ClinicalTrials.gov)
June 18, 202024/3/2020A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)Eosinophilic Gastritis;Eosinophilic DuodenitisDrug: lirentelimab (AK002);Other: PlaceboAllakos, Inc.NULLRecruiting18 Years80 YearsAll160Phase 3United States